Infant Neurobehavior Following Prenatal Exposure to Methadone or Buprenorphine: Results From the Neonatal Intensive Care Unit Network Neurobehavioral Scale

References

• Bauer, C. R., Shankaran, S., Bada, H., Lester, B. M., Wright, L. L., Krause-Steinrauf, H., (2002). The maternal lifestyle study: drug exposure during pregnancy and short-term maternal outcomes. American Journal of Obstetrics and Gynecology, 186: 487–495.
   PubMed Web of Science ®Google Scholar
• Brazelton, T. B. (1984). Neonatal behavioral assessment scale. Philadelphia, PA: JB Lippinicott.
   Google Scholar
• Blinick, G., Wallach, R. C., Jerez, E. (1969). Pregnancy in narcotic addicts treated by medical withdrawal: the methadone detoxification program. American Journal of Obstetrics and Gynecology, 105: 997–1003.
   PubMed Web of Science ®Google Scholar
• Blinick, G., Wallach, R. C., Jerez, E., Ackerman, B. D. (1976). Drug addiction in pregnancy and the neonate. American Journal of Obstetrics and Gynecology, 125: 135–142.
   PubMed Web of Science ®Google Scholar
• Coyle, M. G., Ferguson, A., LaGasse, L., Liu, J., Lester, B. (2005). Neurobehavioral effects of treatment for opiate withdrawal. Archives of Disease in Childhood. Fetal and Neonatal Edition, 90: F73–F74.
   PubMed Web of Science ®Google Scholar
• Dashe, J. S., Jackson, G. L., Olscher, D. A., Zane, E. H., Wendel, G. D., Jr. (1998). Opioid detoxification in pregnancy. Obstetrics and Gynecology, 92: 854–858.
   PubMed Web of Science ®Google Scholar
• Finnegan, L. P. (1986). Neonatal abstinence syndrome: assessment and pharmacotherapy. In F. F. Rubatelli & B. Granati (Eds.), Neonatal therapy: an update (pp. 122–146). New York: Excerpta Medica.
   Google Scholar
• Finnegan, L. P. (1991). Perinatal substance abuse: comments and perspectives. Seminars in Perinatology, 15: 331–339.
   PubMed Web of Science ®Google Scholar
• Hou, Y., Tan, Y., Belcheva, M. M., Clark, A. L., Zahm, D. S., Coscia, C. J. (2004). Differential effects of gestational buprenorphine, naloxone, and methadone on mesolimbic mu-opioid and ORL1 receptor G protein coupling. Brain Research. Developmental Brain Research, 51: 149–157.
   Google Scholar
• Jansson, L. M., Choo, R., Velez, M. L., Harrow, C., Schroeder, J. R., Shakleya, D. M., (2008). Methadone maintenance and breastfeeding in the neonatal period. Pediatrics, 121: 106–114.
   Google Scholar
• Jansson, L. M., DiPietro, J. A., Elko, A., Velez, M. (2007). Maternal vagal tone change in response to methadone is associated with neonatal abstinence syndrome severity in exposed neonates. Journal of Maternal-Fetal & Neonatal Medicine, 20: 677–685.
   PubMed Web of Science ®Google Scholar
• Jansson, L. M., Velez, M., Harrow, C. (2009). The opioid-exposed newborn: assessment and pharmacologic management. Journal of Opioid Management, 5: 47–58.
   PubMedGoogle Scholar
• Jasinski D. R., Preston, K. L. (1995). Laboratory studies of buprenorphine in opioid abusers. In A. Cowan & J. K. Lewis (Eds.), Buprenorphine: combating drug abuse with a unique opioid (pp. 189–211). New York: Wiley-Liss.
   Google Scholar
• Jones, L. V., Tukey, J. W. (2000). A sensible formulation of the significance test. Psychological Methods, 5: 411–414.
   PubMed Web of Science ®Google Scholar
• Jones, H. E., Johnson, R. E., Jasinski, D. R., O’Grady, K., Chisholm, C. A., Choo, R. E. (2005). Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence, 79: 1–10.
   PubMed Web of Science ®Google Scholar
• Kaltenbach, K., Berghella, V., Finnegan, L. (1998). Opioid dependence during pregnancy: effects and management. Obstetrical and Gynecological Clinics of North America, 25: 139–151.
   PubMed Web of Science ®Google Scholar
• Law, K. L., Stroud, L. R., LaGasse, L. L., Niaura, R., Liu, J., Lester, B. M. (2003). Smoking during pregnancy and newborn neurobehavior. Pediatrics, 111: 1318–1323.
   PubMed Web of Science ®Google Scholar
• Lester, B. M., Tronick, E. Z., Brazelton, T. B. (2004). The neonatal intensive care unit network neurobehavioral scale procedures. Pediatrics, 113: 641–667.
   PubMed Web of Science ®Google Scholar
• Lester, B. M., Tronick, E. Z., LaGasse, L., Seifer, R., Bauer, C. R., Shankaran, S., (2002). The maternal lifestyle study: effects of substance exposure during pregnancy on neurodevelopmental outcome in 1-month-old infants. Pediatrics, 110: 1182–1192.
   PubMed Web of Science ®Google Scholar
• Naeye, R. L., Blanc, W., Leblanc, W., Khatamee, M. A. (1973). Fetal complications of maternal heroin addiction: abnormal growth, infections, and episodes of stress. Journal of Pediatrics, 83: 1055–1106.
   PubMed Web of Science ®Google Scholar
• Napiorkowski, B., Lester, B. M., Freier, M. C., Brunner, S., Dietz, L., Nadra, A., (1996). Effects of in utero substance exposure on infant neurobehavior. Pediatrics, 98: 71–75.
   PubMed Web of Science ®Google Scholar
• Smith, L. M., Lagasse, L. L., Derauf, C., Grant, P., Shah, R., Arria, A., (2008). Prenatal methamphetamine use and neonatal neurobehavioral outcome. Neurotoxicology and Teratology, 30: 20–28.
   Web of Science ®Google Scholar
• Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., Bigelow, G. E. (1994). Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clinical Pharmacology & Therapeutics, 55: 569–580.
   PubMed Web of Science ®Google Scholar